Loading
Hepatocellular Carcinoma Treatment and Prognosis / Cancer, Lipids, and Metabolism / Liver Disease Diagnosis and Treatment · Journal article
Hepatoma Research · August 11, 2026
A consensus or society position rather than new primary data.
This is a narrative review assessing pharmacological strategies for HCC chemoprevention in the context of evolving aetiologies, particularly metabolic dysfunction-associated steatotic liver disease. Established approaches (antivirals, vaccination) are effective; statins show the most consistent observational support for MASLD-related HCC prevention, while newer agents (semaglutide, lanifibranor, resmetirom) are biologically plausible but lack direct cancer prevention evidence. The field requires prospective trials and validated biomarkers to establish whether surrogate endpoints (fibrosis regression, steatosis reduction) translate to HCC incidence reduction.
Journal article.
Antiviral therapy and hepatitis B vaccination have proven effective in preventing liver cancer Statins have shown the most consistent observational evidence of benefit for HCC chemoprevention Data for aspirin and metformin are less robust or inconclusive
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
A narrative expert review synthesizing current evidence on pharmacological HCC chemoprevention, identifying established approaches (antivirals, vaccination), agents with observational support (statins), and emerging candidates requiring prospective validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Hepatocellular carcinoma (HCC) remains a major global health challenge and is increasingly linked not only to chronic viral hepatitis and alcohol exposure, but also to metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, and dysglycemia. Advanced fibrosis and cirrhosis are the main precancerous conditions for hepatocarcinogenesis, making chemoprevention a rational strategy for individuals at risk of developing primary HCC or experiencing recurrence after treatment. However, fibrosis regression, steatohepatitis resolution, and steatosis reduction are biologically plausible but unvalidated surrogate endpoints for HCC chemoprevention. While antiviral therapy and hepatitis B vaccination have proven effective in preventing liver cancer, there is currently no established pharmacological approach for MASLD-related HCC. Among available agents, statins have shown the most consistent observational evidence of benefit, while data for aspirin and metformin are less robust or inconclusive. Newer compounds targeting key pathogenic pathways involved in steatosis, inflammation, and fibrogenesis are of significant interest. Semaglutide, lanifibranor, and resmetirom may indirectly reduce HCC risk by improving MASLD-related disease activity, although direct evidence for cancer prevention is still lacking. Other potential candidates, such as angiotensin-converting enzyme inhibitors, aripiprazole, and RNA-based strategies, are still in the investigational stages. Advances in this field will require improved risk assessment, validated biomarkers, and prospective trials to determine whether reducing fibrosis can lead to meaningful reductions in HCC incidence.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.